Abstract: The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.

Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.

Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.

Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.

Abstract: The present invention provides a composition and an improved single dose vaccine against E. rhusiopathiae and an improved single dose vaccine against E. rhusiopathiae and H. parasuis which provides one or more of the following: 1) confers effective immunity against E. rhusiopathiae and/or H. parasuis; 2) decreases the risk of developing clinical signs of E. rhusiopathiae and/or H. parasuis infection; 3) induces an immune response against E. rhusiopathiae and/or H. parasuis; and 4) has a DOI against E. rhusiopathiae and/or H. parasuis of at least four months. The composition or E. rhusiopathiae vaccine as well as the combined E. rhusiopathiae-H. parasuis composition or vaccine each includes a bacterial component of inactivated E. rhusiopathiae bacteria and a suitable adjuvant. The combined E. rhusiopathiae-H. parasuis composition or vaccine further includes an amount of H. parasuis antigen. The vaccines can be administered to animals in any conventional manner.

Abstract: The present invention provides improved vaccination methods for increased protection against ileitis. The methods provide for the vaccination of young animals, preferably piglets, between 10 and 26 days of age, vaccination of pregnant sows during the second or third stages of gestation, and a combination of these methods. Vaccination of the pregnant sows can occur using repeated and/or high doses of Lawsonai antigen prior to farrowing.

Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.

Abstract: An immunogenic composition or vaccine, and method of treatment are provided by the present invention. The immunogenic composition is useful for treating, preventing, and lessening the severity of clinical symptoms associated with disease-causing organisms in swine, utilizing one or more Porcine Teschovirus antigen(s) along with an antigen of the other disease-causing organism in swine and a pharmaceutically acceptable carrier.

Abstract: The present invention is related to methods and attenuated viral compositions for use in preventing and treating a high fever disease forms associated with porcine reproductive and respiratory syndrome (PRRS), such as highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS), a viral disease affecting swine.

Abstract: The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.

Abstract: Methods of reducing the severity of porcine reproductive and respiratory syndrome virus (PRRSV) infections, as well as, methods of preventing such infections are provided. The methods provide for the age-based innoculation of swine with PRRS antigen, preferably Ingelvac® ATP.

Abstract: Improved immunoassays for the protection of antibodies against Lawsonia intracellularis are provided which permit rapid, easy detection of low concentrations of anti-Lawsonia antibodies in animal-derived specimens. The preferred assay is an ELISA assay employing an antigenic extract of L. intracellularis lipopolysaccharide.

Abstract: The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.

Abstract: The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of L. intracellularis of European origin and a method of preparing a lyophilized product containing the attenuated European isolate as vaccine product.

Abstract: The invention relates to the use of omega chain modified prostaglandins as ocular hypotensive. The derivatives used in accordance with the invention are encompassed by the following structure formula I: wherein the hatched segments represent &agr; bonds; the wavy segment represents an &agr; or &bgr; bond; dashed lines represent a double bond or a single bond; X is selected from the group consisting of —OR and N(R2); Y is=O or represents 2 hydrogen radicals, provided that Y represents 2 hydrogen radicals when X is OH; R is hydrogen or a lower alkyl radical having up to six carbon atoms; R1 is=O or hydroxy; m is 0, 2, 4 or 6, provided that m is not 4 when the wavy segment represents a &bgr; bond; n is 0, 2, 4 or 6; x and y are 0 or 1, provided that x is 1 when y is 0 and y is 1 when x is 0; or 9, 11 and/or 15 ester derivatives of said compound of formula I, e.g. a C1 to C6 alkyl ester derivative; or a pharmaceutically acceptable salt thereof.

Abstract: A method for large scale cultivation and attenuation of L. intracellularis bacteria by inoculating cells with L. intracellularis bacteria to infect the cells, incubating the infected cells in a reduced oxygen concentration and maintaining the infected cells in suspension. Anti-L. intracellularis vaccines are prepared from cultures grown in suspension. Diagnostic agents are also disclosed.

Abstract: A method for large scale cultivation and attenuation of IS intracellularis bacteria by inoculating cells with IS intracellularis bacteria to infect the cells, incubating the infected cells in a reduced oxygen concentration and maintaining the infected cells in suspension. Anti-IS intracellularis vaccines are prepared from attenuated strains. Diagnostic agents are also disclosed.

Abstract: Compounds of the formula ##STR1## where the hatched lines indicate alpha (.alpha.) configuration, a solid triangle is used to indicate beta (.beta.) configuration, lines on both sides of a double bond indicate cis (Z) configuration, and lines on opposite sides of the double bond indicate trans (E) configuration; R.sub.1 is alkyl of 1-10 carbons, C.sub.1 -C.sub.10 alkylphenyl, phenyl-C.sub.1 -C.sub.10 alkyl, or alkenyl of 2 to 10 carbons and having 1 to 3 double bonds; R.sub.2 is Z--OR.sub.3, Z--OCOR.sub.3, Z--OCONHR.sub.3, Z--OCOOR.sub.3, Z--NR.sub.4 R.sub.5, Z--NR.sub.4 COR.sub.3, Z--NR.sub.4 SO.sub.2 R.sub.3, Z--COOR.sub.3, Z--CONR.sub.4 R.sub.5, Z--CHO; Z is (CH.sub.2).sub.n where n is 1-6, or Z is an alkenyl group having 2 to 6 carbons and 1 or 2 double bonds, R.sub.3 is H, alkyl of 1-6 carbons, alkenyl of 2 to 6 carbons or phenyl, R.sub.4 and R.sub.5 independently are H or alkyl of 1 to 6 carbons, have ocular hypotensive activity.

Abstract: Intraocular pressure is lowered in the eye of a mammal by administration of a pharmaceutical composition containing as active ingredient a compound of the formula ##STR1## where the dotted line represents a bond or the absence of a bond, wavy lines connected to the olefinic bond represent cis or trans configuration about the olefinic bond; R.sub.1 represents H, or CO-R.sub.3 where R.sub.3 is lower alkyl of 1 to 6 carbons, carbocyclic aryl or heterocyclic aryl; or carbocyclic aryl or heteroaryl substituted lower alkyl group; R.sub.2 represents H or lower alkyl of 1 to 6 carbons, and n is an integer between 0 and 8.